Privium Fund Management B.V. Dyne Therapeutics, Inc. Transaction History
Privium Fund Management B.V.
- $354 Million
- Q2 2024
A detailed history of Privium Fund Management B.V. transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Privium Fund Management B.V. holds 14,016 shares of DYN stock, worth $485,233. This represents 0.14% of its overall portfolio holdings.
Number of Shares
14,016Holding current value
$485,233% of portfolio
0.14%Shares
1 transactions
Others Institutions Holding DYN
# of Institutions
201Shares Held
106MCall Options Held
82.7KPut Options Held
24.8K-
Atlas Venture Life Science Advisors, LLC8.02MShares$278 Million37.7% of portfolio
-
Fcpm Iii Services B.V. Naarden, P77.85MShares$272 Million40.83% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$256 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY6.39MShares$221 Million3.76% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$209 Million3.22% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $1.79B
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...